

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACCORD BIOPHARMA, INC., INTAS PHARMACEUTICALS LTD., AND
BIO-THERA SOLUTIONS, LTD.,
Petitioners,

v.

JANSSEN BIOTECH, INC.,
Patent Owner.

Case No. IPR2026-00256
Patent No. 11,014,982

Case No. IPR2026-00257
Patent No. 11,041,020

IPR2026-00258
Patent No. 12,122,824

IPR2026-00259
Patent No. 12,291,566

DECLARATION OF MR. CHRYS KOKINO

Accord BioPharma, Inc.
Exhibit 1053
Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 1053-001

I, Chrys Kokino, hereby declare as follows:

1. I am President U.S. Specialty of Accord Healthcare, Inc. and President of U.S. BioPharma at Accord BioPharma, Inc. (together, “Accord”), and I have personal knowledge of the facts set forth in this declaration. If called as a witness, I could and would testify competently thereto.

2. Accord is an American company incorporated in Delaware and headquartered in Raleigh, North Carolina, focused on expanding domestic access to biosimilar therapies that will lower healthcare costs in the United States.

3. Accord has been operating in the United States since 2009 with hundreds of millions in U.S. annual sales.

4. Accord employs hundreds of Americans and has made massive direct investments to expand its U.S. footprint, including processing and manufacturing Udenyca in the U.S. following the acquisition of the Udenyca franchise from Coherus BioSciences, Inc. (another American company) in 2025. *See, e.g.*, EX1056 (Apr. 14, 2025 Press Release). Relatedly, in early 2026, Accord’s parent company, Intas Pharmaceuticals Limited, acquired a U.S. entity, ForDoz Pharma Corp. (“ForDoz Pharma”), including a pharmaceutical manufacturing facility in New Jersey. Accord also retained all of the employees of ForDoz Pharma.

5. Accord is one of the Petitioners in this IPR, and Accord controls this IPR and related district court litigation for Petitioners.

Privileged and Confidential

6. The biosimilar application for BAT2506 (BLA No. 761452) belongs to Accord, and Accord will conduct the U.S. commercial marketing, sales, and distribution and manage the domestic supply chain for BAT2506.

7. Accord is not currently pursuing regulatory approval at the FDA for the treatment of Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) covered by the challenged claims. *See, e.g.*, EX1057 (May 18, 2026 Press Release).

8. Accord's U.S. sales force met in Las Vegas this June and will be selling the golimumab biosimilar once approved. The following image (EX1054) is a photograph of Accord's U.S. team from this meeting:



9. Accord has secured seven U.S. biosimilar approvals over the past two years, including three U.S. biosimilar approvals in the first half of 2026.

10. Accord's golimumab biosimilar will be introduced at a discount to branded pricing, saving money for American patients, plans, and the U.S. government.

Privileged and Confidential

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

A handwritten signature in cursive script, appearing to read "George Kokind". The signature is written in dark ink on a light background.

Executed on June 26, 2026, at Mendham, New Jersey.